FPS Flashcards

1
Q

What is the benefit of Continuous Manufacturing?

A

More efficient

Safer, due to no manual handing

Smaller equipment and facilities

Smaller ecological footprint

Lower costs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 3 levels of State Control Requirements for Continous Manufacturing?

A

Level 1 –> Active control systems with real-time monitoring of quality attributes (Flexible CPPs to allow for variability in CMAs)

Level 2 –> Reduced end product testing and operation within established ranges and confirmed with final tests

Level 3 –> Inability to test for quality without end product testing. Not very flexible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why is Hybrid Continous Manufacturing done?

A

As the API needs to be made via batch manufacturing as they’re made in free trade zones (to avoid tax)

Once the API is in the country/factory, then the rest of the process is done via continous manufacture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Explain what Portable Continuous, Miniature and Modular (PCMM) Manufacturing is….and the benefits that it brings

A

A modular factory with standardized ‘plug and play’ equipment

This allows a rapid changeover of drug production (different drugs), flexbile batch sides and production-on-demand

Also give more real-time monitoring with multiple analysers incorprated

Fully automated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the main benefits of having a greater Sigma Process in manufacturing?

A

Less defects (ppm), greater yields and decreased cost for quality!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The Pharmaceutcial world are currently operating at 2-3 Sigma….what does this mean?

A

Treating symptoms and not the route cause (of quality)

Measurments that are done are done because they can be….not because they should be (meaning that some measurments just aren’t done)

Lack of understanding as to why things are done…but just acceptance that they are

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Quality by Design?

A

Aligned with Kaizen principles

Aim is to create products with quality built into them by planning, and not by chance –> If this is done then end-product testing isn’t needed as we know that it is of quality

Enables continuous improvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the benefits of QbD?

A

Reduces development time

Minimises product cost

Useful when troubleshooting

More efficinent timing of product releases

Allows maintainence of the product life cycle with greater ease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the The Quality Triology?

A

Quality Planning –> Plan and define the quality requirements of the end product

Quality Control –> Variability in product and proccesses need to controlled by scientific tools and risk-based statistical tools for monitoring end-product quality

Quality Improvement –> A contiunous process throughout the drugs lifecycle by regulating controls

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the 5 steps of implementing QbD?

A

Define the Quality Target Product Profile (QTPP) –> Planning quality before production has even started

Identifiy the Critical Quality Attributes (CQAs) –> The key quality attributes for the drug

There are final and intermediate CQAs

Identify the Critical Material Attributes (CMAs) and Critical Processing Parameters (CPPs) –> These are vital in ensuring that the CQAs are met

Design Space Development –> Explores the relationship between material/process inputs and CQAs

Allows manufacturers to prove to authorities that they understand their process

Quality Control and Continous Improvement –> These control can include in-process measurments and end-product testing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is Olaparib?

And what are the major issues with it?

A

A PARP inhibitor (inhibiting cell repair) for those with BRCA1/2 mutations

Issues –> Solubility and permability

Led to it having to be formulated as a Hot-Melt Extrusion (HME) tablet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the 4 reasons for poor asthma control in general?

A

Therapy resistent disease

Social Factors –> Environment

Behavioural Factors –> Adherence and inhaler technique

Psychological Factors –> Anxiety and depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What 3 things do people with asthma need in order to increase adherence?

A

To realize the neccesity of the medication

To negotiate their concerns about treatment

Support for the emotional aspects of their disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is disruption?

A

A radical change in industry or a business strategy

Eg, 3D printing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why is the rate of synthesis of monoamines relatively slow?

A

As after entering the synaptic cleft they can be reuptaken into the neurone

So they are reused!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the transporter that allows dopamine to be reuptaken into the neurone, and also has an allosteric binding site that cocaine can bind to?

A

Dopamine Reuptake Transporter (DAT)

Also could be how amphetamines are released into the synaptic cleft

17
Q

Naturally, where is the concentration of monoamines greater?

Neurones or the cleft?

A

The cleft!

So reuptake is working ag ainst a concentration gradient

18
Q

How does the 3D structure of monoamine reuptake inhibitors differ from that of monoamine releasing agents?

A

Reuptake Inhibitors –> Bulky 3D structures with high affinity for the reuptake transporter

Releasing Agents –> Small molecules with low affinity for the reuptake transporter

19
Q

How does the onset of action and the duration of action of monoamine reuptake inhibitors differ from that of monoamine releasing agents?

A

Reuptake Inhibitors –> Slow onset (and so low concentrations) but prolonged duration

Releasing Agents –> Rapid onset (and so high concetrations) but for a short duration

20
Q

How do monoamine releasing agents actually decrease the amount of monoamine that is reuptaken?

A

Via competitive inhibiton!

They are uptaken instead of monoamines, meaning that naturally less monoamines can be reuptaken

21
Q

Neuronal firing is important for one of monoamine reuptake inhibitors or releasing agents….which one?

A

Reuptake inhibitors

22
Q

Which are more specific….monoamine or reuptake inhibitors or releasing agents?

A

Reuptake inhibitors

Although they’re still not very specific

23
Q

Where is the site of action for the following…

Monoamine reuptake inhibitors

Monoamine releasing agents

A

Monoamine reuptake inhibitors –> Extraneuronal

As they block the transporter from the outside

Monoamine releasing agent –> Intraneuronal

As they move inside the neurone

24
Q

Explain the process of CAR T therapy

A

T cells are removed from the patient via leukapheresis

They are then genetically altered by adding the Chimeric Antigen Receptor (CAR) to their surface, which contains CD3 and CD28 (and other co-stimulatory signals)…..this enables the cells to target the specific cancer cells and kill them

These recombinant cells are then cultured in the lab until there are billions, before being injected back into the patient for treatment

25
Q

What is the main possible adverse effect from CAR T therapy?

A

Cytokine Release Syndrome (CRS)

Where T cells proliferate through the body creating a large inflammatory response

Marked by an increase in IL-6 along with other cytokines